Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + bevacizumab + paclitaxel as second-line therapy for HER2-positive gastric cancer
KCT0008209Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, bevacizumab, paclitaxel in Gastric cancer (HER2-positive), sponsored by Boryung. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
03
Conditions
Gastric cancer (HER2-positive)
Beyond the preview
Go deeper on KCT0008209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008209.